Recruiting

Testing a new vaccine and cell therapy combination for advanced stomach cancer

Plain-English translation of NCT07298200 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing whether combined with a personalized neoantigen vaccine and tumor-fighting T-cell therapy can safely treat advanced stomach cancer. The treatment works by teaching your immune system to recognize and attack cancer cells using a vaccine tailored to your tumor. Researchers want to see if this combination approach is safe, well-tolerated, and effective at shrinking tumors or extending survival.

Advanced stomach cancer often stops responding to standard chemotherapy treatments, leaving patients with limited options. This trial explores whether boosting the immune system with a personalized vaccine and specialized immune cells could offer a new path forward for patients whose cancer has resisted conventional therapy.

Do you qualify?

You likely qualify if…

you have advanced stomach cancer that has either not responded to second-line chemotherapy or that you cannot tolerate
you are between 18 and 70 years old
you have at least one tumor that can be measured on imaging and is under 30mm in size
your doctors expect you to survive at least 12 weeks
your heart, liver, kidneys, and bone marrow are working well enough to handle the treatment

You likely don't qualify if…

you have cancer that has spread to your brain or around your spinal cord without prior treatment
you have taken immune-boosting drugs within the past 2 weeks
you are currently taking high-dose steroids (more than 10mg prednisone daily) or other immune-suppressing medications
you have active, serious infections or positive tests for HIV, hepatitis B (with active virus), hepatitis C, or syphilis
you have had other cancers in the past 5 years (with limited exceptions for skin and cervical cancers caught early)

What participation looks like

You would receive injections of XH001 vaccine and a specialized T-cell therapy at the study center. The trial will monitor you closely to watch for any side effects and to measure whether your tumors shrink or stay stable. You'll be followed by the research team throughout the study to ensure your safety and to track how well the treatment is working.

AI-generated summary from trial data · Jul 9, 2026 · Not medical advice

Trial locations(1 site)

China

Nanjing Drum Tower Hospital, Nanjing, Jiangsu